ERBB2 and neoplasm: In the subgroup analysis of different subtypes, the pooled results showed that, although each 10% increment of TILs in luminal tumor phenotype did not significantly improve OS (HR, 1.06; 95% CI, 0.99–1.13) (eFigure 1, Supplementary page 1), the improvements in OS were attained by it in HER2-overexpression (HR, 0.92; 95% CI, 0.89–0.95) (eFigure 2, Supplementary page 1) and TN (HR, 0.90; 95% CI, 0.89–0.92) subtypes (eFigure 3, Supplementary page 2).